Bedinvetmab, alone or in combination with photobiomodulation and pulsed electromagnetic field therapy, on pain and quality of life in dogs with hip osteoarthritis.

Osteoarthritis (OA) is one of the main causes of chronic pain in dogs, significantly impairing mobility and quality of life. This study aimed to evaluate the analgesic efficacy of bedinvetmab, administered alone and in combination with physiotherapy using photobiomodulation (PBM) and pulsed electromagnetic field therapy (PEMF), in dogs with hip OA. This was a prospective, randomized, comparative effectiveness trial involving 30 dogs allocated into two groups: BPG (bedinvetmab + physiotherapy) and BG (bedinvetmab). In the BPG, physiotherapy sessions were performed twice a week throughout the 90-day protocol. Pain was assessed through algometry and the Canine Brief Pain Inventory (CBPI) completed by the owners. Both groups showed significant clinical improvement (p < 0.001). In the CBPI, both the Pain Severity Score (PSS) and Pain Interference Score (PIS) decreased significantly from baseline to day 90 in both groups. In algometry, the BPG showed a significant increase in pain threshold as early as day 15 (D15) and was superior to the BG from day 30 (D30; p = 0.027), with more pronounced differences at days 60, 75, and 90 (D60, D75, and D90; p < 0.001). These findings provide preliminary evidence that the combination of bedinvetmab and physiotherapy enhances pain control and promotes better quality of life in dogs with OA.